Aaron is the Founder of Simcha Therapeutics and a widely-recognized leader in cytokine engineering for which he was named to Endpoints “20 under 40 in Biopharma in 2022” and Nature Biotechnology’s “Top 20 Translational Researchers of 2020.” He led the development of decoy-resistant IL-18 in his laboratory at the Yale School of Medicine where he is an Associate Professor of Immunobiology.